Saltar al contenido
Merck
Todas las fotos(1)

Documentos

SML2743

Sigma-Aldrich

TM30089

≥98% (HPLC)

Sinónimos:

2-(3-(4-Fluoro-N-methylphenylsulfonamido)-3,4-dihydro-1H-carbazol-9(2H)-yl)acetic acid, 3-[[(4-Fluorophenyl)sulfonyl]methylamino]-1,2,3,4-tetrahydro-9H-carbazole-9-acetic acid, CAY 10471, CAY-10471, CAY10471, TM 30089, TM-30089, {3-[(4-Fluorobenzenesulfonyl)methylamino]-1,2,3,4-tetrahydrocarbazol-9-yl}acetic acid

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización
Todas las fotos(1)

About This Item

Fórmula empírica (notación de Hill):
C21H21FN2O4S
Número de CAS:
844639-57-2
Peso molecular:
416.47
Número MDL:
MFCD08062186
Código UNSPSC:
12352200
NACRES:
NA.77

Nivel de calidad

100

Análisis

≥98% (HPLC)

formulario

powder

color

white to beige

solubilidad

DMSO: 2 mg/mL, clear

temp. de almacenamiento

−20°C

InChI

1S/C21H21FN2O4S/c1-23(29(27,28)16-9-6-14(22)7-10-16)15-8-11-20-18(12-15)17-4-2-3-5-19(17)24(20)13-21(25)26/h2-7,9-10,15H,8,11-13H2,1H3,(H,25,26)

Clave InChI

CANCTKXGRVNXFP-UHFFFAOYSA-N

Acciones bioquímicas o fisiológicas

TM30089 is a ramatroban analog and an orally active, high-affinity, potent and selective prostaglandin D2 receptor 2 (DP2; CRTH2) antagonist (Ki = 0.6 nM/hDP2 against 1.2 nM PGD2; Ki = 1.2 μM/hDP1 against 0.5 nM PGD2, >10 μM/hTP against 5 nM SQ29548) that blocks PGD2-induced responses in hDP2 transfectants (IP1/βarr IC50 = 1.2/3.0 nM) and exhibits in vivo efficacy in a murine model of renal tubulointerstitial fibrosis (20 mg/kg b.i.d. p.o., starting 4 days before or 3 days after unilateral ureteral obstruction/UUO).

Pictogramas

Exclamation markEnvironment
GHS07,GHS09

Palabra de señalización

Warning

Frases de peligro

H315,H317,H319,H410

Clasificaciones de peligro

Aquatic Acute 1 - Aquatic Chronic 1 - Eye Irrit. 2 - Skin Irrit. 2 - Skin Sens. 1

Código de clase de almacenamiento

11 - Combustible Solids

Clase de riesgo para el agua (WGK)

WGK 3

Certificados de análisis (COA)

Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»

¿Ya tiene este producto?

Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

Visite la Librería de documentos

Trond Ulven et al.
Journal of medicinal chemistry, 48(4), 897-900 (2005-02-18)
Ramatroban, a thromboxane A(2) receptor (TP) antagonist with clinical efficacy in asthma and allergic rhinitis, was recently shown to also antagonize the prostaglandin D(2) receptor CRTH2. Here we report that minor structural changes to ramatroban result in a compound (13)
Go Eun Choi et al.
The Journal of allergy and clinical immunology, 141(3), 938-950 (2017-12-12)
Eosinophilic inflammation is a major pathologic feature of chronic rhinosinusitis (CRS) and is frequently associated with severe refractory disease. Prostaglandin (PG) D2 levels are increased in patients with CRS, and PGD2 is an important contributing factor to eosinophilic inflammation. Autophagy
Hideyuki Ito et al.
Journal of the American Society of Nephrology : JASN, 23(11), 1797-1809 (2012-09-22)
Urinary excretion of lipocalin-type PGD(2) synthase (L-PGDS), which converts PG H(2) to PGD(2), increases in early diabetic nephropathy. In addition, L-PGDS expression in the tubular epithelium increases in adriamycin-induced nephropathy, suggesting that locally produced L-PGDS may promote the development of
Miriam Peinhaupt et al.
Journal of leukocyte biology, 104(1), 159-171 (2018-04-03)
Prostaglandin (PG) D2 is the ligand for the G-protein coupled receptors DP1 (D-type prostanoid receptor 1) and DP2 (also known as chemoattractant receptor homologous molecule, expressed on Th2 cells; CRTH2). Both, DP1 and DP2 are expressed on the cellular surface
David F Woodward et al.
FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 31(1), 368-375 (2016-10-23)
The purpose of these studies was to test the hypothesis that a selected polypharmacological approach for treating the prostanoid-mediated component of inflammatory diseases would produce a therapeutic effect superior to global inhibition of prostaglandin (PG) biosynthesis by aspirin-like drugs. The

Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

Póngase en contacto con el Servicio técnico